Molecular analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/everolimus

The mTORC1 inhibitor everolimus (Afinitor/RAD001) has been approved for multiple cancer indications, including ER(+)/HER2(−) metastatic breast cancer. However, the combination of everolimus with the dual PI3K/mTOR inhibitor BEZ235 was shown to be more efficacious than either everolimus or BEZ235 alo...

Descripción completa

Detalles Bibliográficos
Autores principales: Brannon, A. Rose, Frizziero, Melissa, Chen, David, Hummel, Jennifer, Gallo, Jorge, Riester, Markus, Patel, Parul, Cheung, Wing, Morrissey, Michael, Carbone, Carmine, Cottini, Silvia, Tortora, Giampaolo, Melisi, Davide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory Press 2016
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4849849/
https://www.ncbi.nlm.nih.gov/pubmed/27148582
http://dx.doi.org/10.1101/mcs.a000620

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4849849/
https://www.ncbi.nlm.nih.gov/pubmed/27148582
http://dx.doi.org/10.1101/mcs.a000620

Ejemplares similares